Angiogenesis is one of the most impressive hallmarks of CRC [39,40,41,42] because, at the basis of tumor growth and metastasization, the latter occurring mainly via lymphatics, CRC angiogenesis is driven by VEGF signaling acting through tyrosine receptor kinases, VEGFR1 and VEGFR2 are implicated in blood vessel development and branching, and VEGFR3 is implicated in lymphangiogenesis [43], so that antiangiogenic therapies resulted effective in CRC treatment, mainly in patients with liver metastasis [43]. The gene discussed is FLT1; the disease is colorectal carcinoma.